Ionis Pharmaceuticals shares rose 2.2% this morning to a price of $82.7. The stock is still trading within range of its average target price of $85.47, and over the last 52 weeks, it has recorded a 131.5% performance. Analysts have given the Large-Cap Pharmaceutical stock target prices ranging from $47.0 to $116.76 dollars per share, with an average rating of buy.
Ionis Pharmaceuticals has an elevated short interest of 11.6%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 5.2. At 0.62%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation. 106.5% of Ionis Pharmaceuticals shares are held by institutional investors, which indicates a high level of confidence in the stock.
Institutions Invested in Ionis Pharmaceuticals
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-09-30 | FMR, LLC | 15% | 23,689,038 | $1,959,083,370 |
| 2025-09-30 | Vanguard Group Inc | 10% | 16,481,730 | $1,363,039,020 |
| 2025-09-30 | T. Rowe Price Investment Management, Inc. | 8% | 13,156,929 | $1,088,077,988 |
| 2025-09-30 | Capital World Investors | 8% | 12,722,728 | $1,052,169,566 |
| 2025-09-30 | Blackrock Inc. | 6% | 10,447,940 | $864,044,606 |
| 2025-09-30 | Wellington Management Group, LLP | 4% | 6,588,811 | $544,894,649 |
| 2025-09-30 | Bellevue Group AG | 4% | 6,244,451 | $516,416,078 |
| 2025-09-30 | State Street Corporation | 3% | 4,388,651 | $362,941,424 |
| 2025-09-30 | Deep Track Capital, Lp | 2% | 3,808,144 | $314,933,497 |
| 2025-09-30 | Geode Capital Management, LLC | 2% | 3,066,289 | $253,582,090 |
For these reasons, we consider that the Ionis Pharmaceuticals is the subject of mixed market sentiment.
